COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy

Hadji, Peyman; Jackisch, Christian; Bolten, W.; Blettner, Maria; Hindenburg, HJ; Klein, Peter; König, Kai; Kreienberg, R.; Rief, Winfried; Wallwiener, D.; Zaun, Silke; Harbeck, Nadia

doi:10.1093/annonc/mdt513

Cited by 63 publications

(48 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysis of longitudinal claims data from three American commercial health programs revealed sub-optimal adherence to anastrozole in 19-28% of patients in their first year of treatment (14). These statistics are consistent with other studies of aromatase inhibitor adherence (15)(16)(17)(18), which report a significant percentage of patients displaying early discontinuation of treatment. There are important clinical implications of this data, as non-compliance with adjuvant endocrine therapies in early breast cancer has been shown to be detrimental to the patients' survival (16).…”

Section: Introductionsupporting

confidence: 84%

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis

Roberts

Rickett

Greer

et al. 2017

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 84%

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis

Roberts

Rickett

Greer

et al. 2017

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Other trials have also reported on the influence of preexisting joint and muscle/limb pain on musculoskeletal pain syndrome during treatment with AIs . The severity of pain during AI treatment has also been evaluated in other studies . In the COMPACT trial, arthralgia during the first year of anastrozole was assessed using a visual analog scale.…”

Section: Discussionmentioning

confidence: 99%

Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients

Nabieva

Häberle

Brucker

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

One of the most common adverse events (AEs) occurring during treatment with aromatase inhibitors (AIs) is musculoskeletal pain. The aim of our study was to analyze the influence of preexisting muscle/limb pain and joint pain on the development of AI‐induced musculoskeletal AEs. Women eligible for upfront adjuvant endocrine therapy with letrozole were included in the PreFace study, a multicenter phase IV trial. During the first treatment year, they were asked to record musculoskeletal AEs monthly by answering questions regarding pain symptoms and rating the pain intensity on a numeric rating scale from 0 (no pain) to 10 (very strong pain). Pain values were compared using nonparametric statistical tests. Overall, 1,416 patients were evaluable. The average pain value over all time points in women with preexisting muscle/limb pain was 4.3 (median 4.3); in those without preexisting pain, it was 2.0 (median 1.7). In patients without preexisting muscle/limb pain, pain levels increased relatively strongly within the first 6 months (mean increase +0.9, p < 0.00001) in comparison with those with preexisting pain (mean increase +0.3, p < 0.001), resulting in a statistically significant difference (p < 0.00001) between the two groups. The development of joint pain was similar in the two groups. Women without preexisting muscle/limb pain or joint pain have the greatest increase in pain after the start of adjuvant AI therapy. Women with preexisting pain have significantly higher pain values. The main increase in pain values takes place during the first 6 months of treatment.

show abstract

“…Скелетно-мышечные осложнения являются наиболее частой причиной досрочного прекращения ГТ [45,46]. К ним относятся артромиалгии, а также потеря костной плотности/остеопения, остеопороз и переломы.…”

Section: скелетномышечные осложнения ингибиторов ароматазыunclassified

Adverse effects of adjuvant endocrine therapy

et al. 2018

View full text Add to dashboard Cite

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy

Abstract: NCT00857012.

Cited by 63 publications

References 26 publications

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis

Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients

Adverse effects of adjuvant endocrine therapy

Contact Info

Product

Resources

About